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A defect in myoblast fusion underlies
Carey-Fineman-Ziter syndrome
Silvio Alessandro Di Gioia1,2,3, Samantha Connors4,*, Norisada Matsunami5,*, Jessica Cannavino6,*,
Matthew F. Rose1,2,7,8,9,10,*, Nicole M. Gilette1,2, Pietro Artoni1,2,3, Nara Lygia de Macena Sobreira11,
Wai-Man Chan1,2,3,12, Bryn D. Webb13, Caroline D. Robson14,15, Long Cheng1,2,3, Carol Van Ryzin16,
Andres Ramirez-Martinez6, Payam Mohassel17,18, Mark Leppert5, Mary Beth Scholand19, Christopher
Grunseich18, Carlos R. Ferreira16, Tyler Hartman20, Ian M. Hayes21, Tim Morgan4, David M. Markie22,
Michela Fagiolini1,2,3, Amy Swift16, Peter S. Chines16, Carlos E. Speck-Martins23, Francis S. Collins16,24,
Ethylin Wang Jabs11,13, Carsten G. Bo¨nnemann17,18, Eric N. Olson6, Moebius Syndrome Research Consortiumw,
John C. Carey25, Stephen P. Robertson4, Irini Manoli16, Elizabeth C. Engle1,2,3,8,10,12,26,27
Multinucleate cellular syncytial formation is a hallmark of skeletal muscle differentiation. Myomaker,
encoded byMymk (Tmem8c), is a well-conserved plasma membrane protein required for myoblast fusion to
form multinucleated myotubes in mouse, chick, and zebrafish. Here, we report that autosomal recessive
mutations in MYMK (OMIM 615345) cause Carey-Fineman-Ziter syndrome in humans (CFZS; OMIM
254940) by reducing but not eliminating MYMK function. We characterize MYMK-CFZS as a congenital
myopathy with marked facial weakness and additional clinical and pathologic features that distinguish it
from other congenital neuromuscular syndromes. We show that a heterologous cell fusion assay in vitro
and allelic complementation experiments in mymk knockdown and mymkinsT/insT zebrafish in vivo can dif-
ferentiate between MYMK wild type, hypomorphic and null alleles. Collectively, these data establish that
MYMK activity is necessary for normal muscle development and maintenance in humans, and expand the
spectrum of congenital myopathies to include cell-cell fusion deficits.
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C
arey-Fineman-Ziter (CFZS; OMIM 254940) is an epon-
ymous syndrome described in two siblings who had
marked bilateral facial weakness, Robin sequence (man-
dibular hypoplasia, hypoglossia, cleft palate), inability to fully
abduct both eyes, characteristic facial dysmorphisms, generalized
muscle hypoplasia with hypotonia and relatively mild proximal
weakness, failure to thrive, delayed motor milestones, scoliosis,
and normal intelligence1,2. Reports of children subsequently
diagnosed with CFZS have differed from the original siblings by
also having intellectual disabilities, seizures, and/or brain
malformations or calcifications, raising concerns that they may
not represent the same disease entity2–7. Many of these
subsequent cases had facial weakness and complete absence of
ocular abduction, thus meeting diagnostic criteria for Moebius
syndrome8. In an effort to identify the genetic etiology of CFZS,
we enrolled the original CFZS pedigree and additional sibling
pairs and simplex cases with similar phenotypes together with
their family members into ongoing genetic studies at six medical
institutions. By exome and Sanger sequencing, we now identify
compound heterozygous or homozygous MYMK (TMEM8C)
missense mutations in affected members of four CFZS sibling
pairs and one simplex case.
During embryogenesis, myoblast precursors migrate from pre-
somitic mesoderm to the site of muscle formation, where they
then fuse to form multinucleate myotubes and ultimately
myofibers9,10. Multinucleated myofibers then confer distinct
biomechanical advantages to mature muscles by transducing
force between remote skeletal attachments. Myomaker, encoded
by Mymk, mediates the fusion of mononuclear myoblasts to form
multinucleate myocyte syncytia during muscle development in
mouse11, chick12 and zebrafish13,14. Mymk / mice have a
paucity of skeletal muscle and die perinatally, while heterozygotes
(Mymkþ / ) are indistinguishable from wild-type (WT)
littermates11. Moreover, Mymk /LoxP conditional knockout
mice under the control of a muscle satellite cell specific
promoter have defective muscle regeneration15.
Phenotypic evaluation of the affected participants in this study
defines MYMK-CFZS as a congenital myopathy with marked
facial weakness and additional clinical and pathologic features
that distinguish it from other congenital neuromuscular syn-
dromes and from Moebius syndrome. Heterologous cell fusion
assays and zebrafish modelling demonstrate that MYMK muta-
tions cause CFZS by reducing but not eliminating MYMK
function. Collectively, these data establish that MYMK activity is
necessary for normal muscle development and maintenance in
humans, and expand the spectrum of congenital myopathies to
include cell–cell fusion deficits.
Results
Mutations in MYMK cause CFZS. To identify the genetic
etiology of CFZS, three laboratories each independently generated
and analysed exome sequence data from one of three unrelated
non-consanguineous families, each with two affected siblings with
similar phenotypes (Families 1–3, Figs 1a and 2a, Table 1). Exome
analysis was performed to identify recessive variants with minor
allele frequencies (MAF) ofo0.01. Among the genes harbouring
recessive variants identified in each family, only MYMK was
common to all three (Supplementary Table 1a–c). The affected
siblings in USA Family 1 (individuals 1 and 2), the original CFZS
pedigree1,2, inherited MYMK c.271C4A (p.Pro91Thr,
rs776566597, M1) and c.553T4C (p.Cys185Arg, M2) from
their father and mother, respectively. The affected siblings in
New Zealand Family 2 (individuals 3 and 4) and the affected
siblings in USA Family 3 (individuals 5 and 6) each inherited M1
and c.298G4A (p.Gly100Ser, M3) from their father and mother,
respectively (Fig. 1a,b and Table 1). Variants and their co-
segregation were validated by Sanger sequencing (Supplementary
Fig. 1a).
To define the phenotypic heterogeneity among individuals
harbouring MYMK variants, MYMK exons and flanking intron-
exon boundaries were sequenced in 4300 additional probands
with congenital facial weakness who were referred with the
following diagnoses: CFZS (1 proband); congenital myopathy
with predominant facial weakness with micro/retrognathia (B10
probands); isolated or syndromic congenital facial weakness and
normal eye movements (B50 probands); and Moebius syndrome
(B250 probands). Among these, MYMK variants were identified
in two individuals: an affected child from the USA who had been
misdiagnosed with Moebius syndrome inherited M1 from her
father and c.2T4A (p.0?, M4) from her mother (Family 4,
individual 7); and an affected child from a consanguineous
Brazilian pedigree diagnosed with CFZS was homozygous for a
c.461T4C (p.Ile154Thr, M5) variant (Family 5, individual 8; the
affected sibling was not enrolled in the study; Fig. 1a, Table 1,
Supplementary Fig. 1a). Sequencing also revealed nine known
polymorphisms, none of which were found in combination with
other compound heterozygous changes (Supplementary
Table 1d).
Among the 5 MYMK missense variants, only M1 is present in
the Exome Aggregation Consortium (ExAC) database16; it has a
cumulative MAF of 0.0013 (0.002 for Europeans) and is reported
in the homozygous state in one individual with no declared
phenotype who is not recontactable. We constructed and
compared families’ haplotypes surrounding the MYMK locus.
The four families segregating M1 are haploidentical within a
41 kb region, suggesting a common origin for this allele. By
contrast, the two pedigrees segregating M3 share maximum
haploidentity of 1.4 kb, suggesting that this variant, present in a
CpG dinucleotide and therefore prone to mutation17, arose
independently (Supplementary Fig. 1b). MYMK is predicted to
have seven transmembrane (TM) domains with amino- and
carboxyl-termini located extracellularly and intracellularly,
respectively18. The five corresponding amino acid substitutions
alter phylogenetically highly conserved residues and are predicted
to be deleterious by SIFT and Polyphen2 (Fig. 1b,c, and
Supplementary Table 1e).
The CFZS phenotype differs from other congenital syndromes.
To define the MYMK human phenotype, we examined affected
individuals and determined the penetrance of their clinical fea-
tures and laboratory test results (Fig. 2, Table 1, Supplementary
Fig. 2). All eight affected individuals had congenital bilateral facial
weakness, upturned/broad nasal tip, micro/retrognathia, gen-
eralized muscle hypoplasia with mild axial and appendicular
weakness, delayed motor milestones, and normal cognition. None
had abducens nerve palsy, although mild to minimal eye move-
ment limitations were noted in extreme positions of gaze. Both
males also had cryptorchidism, while the penetrance of eleven
additional clinical features was reduced (Fig. 2a, Supplementary
Fig. 2a–e, Table 1). Notably, all eight individuals achieved inde-
pendent mobility in childhood, and none reported significant
progression of appendicular muscle weakness, required assistance
with ambulation, or have shown susceptibility to malignant
hyperthermia. Individuals 1 and 2, the eldest participants and
siblings, both had nocturnal hypoventilation and developed
restrictive pulmonary disease and pulmonary hypertension after
age 35 years, from which individual 1 died at the age of 37 years.
They also had a family history of idiopathic pulmonary hyper-
tension, and individual 2 has had very slowly progressive axial
weakness. Therefore, it remains to be determined if pulmonary
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hypertension and/or adult-onset progressive weakness are fea-
tures of MYMK CFZS. When obtained, brain magnetic resonance
images (MRI) were normal (Table 1, Supplementary Fig. 2f).
Affected individuals had no fasciculations or other clinical signs
of peripheral nerve involvement, electromyogram/nerve conduc-
tion studies (EMG/NCS) revealed myopathic (and not neuro-
genic) changes, and Mymk expression was not detected in adult
mouse sciatic nerve (Table 1, Supplementary Figs 2g,h and 3u),
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supporting the absence of a neurogenic component to CFZS.
Muscle MRI revealed fatty infiltration predominantly affecting
the adductor magnus and sartorius muscles, and to a lesser degree
the paraspinal and glutei maximi muscles. More pronounced
changes were observed in the oldest living participant (Individual
2; Fig. 2b,c, Table 1, Supplementary Fig. 2h). Scoring the presence
or absence of a maximum of 19 clinical and 4 laboratory features
revealed variability over the cohort with scores ranging between
68 and 96% for a given affected individual (Table 1).
Individual 2 underwent biopsy of the right vastus lateralis
muscle at 15 years of age. Histologic analysis revealed a
disproportionately high number (60%) of variably sized type I
(slow) fibers, many of which were atrophic/hypotrophic, poly-
gonal, and often present in small groups. In contrast, type II (fast)
fibers were consistently hypertrophic with cross-sectional areas
measuring 330% of control type II fibers19–22 (Fig. 2d–i). This
type I fiber type predominance and hypotrophy with type II fiber
hypertrophy meets the diagnostic criteria for congenital fiber type
disproportion myopathy (CFTD). Additional staining and
analyses (Supplementary Fig. 3a–t) showed no rods, cores,
reciprocal type II fiber grouping, or increased central or
number of nuclei. The biopsy also lacked features of
dystrophies, myositis, storage diseases, or mitochondrial
myopathies. Notably, Individual 2 had a prior quadriceps
biopsy as a toddler that was reported to show a slight reduction
in fiber size and a moderate increase in perimysial connective
tissue. Thus, while a few regenerating fibers with myogenin-
positive nuclei were identified (Supplementary Fig. 3j,o), the
appearance of the more distinctive muscle biopsy features shown
here that developed later in childhood, and the greater degree of
fatty infiltration of affected muscles in the older compared to the
younger participants support reduced regenerative capacity.
CFZS results from MYMK null or hypomorphic alleles. Unlike
Mymk / mice, CFZS patients survive and thus may retain
residual MYMK function. Therefore, based on the combinations
of genotypes harboured by the affected individuals, we hypothe-
sized that M1 and M5 were hypomorphic and M2, M3, and M4
were null alleles (Supplementary Fig. 4). To evaluate this
hypothesis, we first tested the effect of the variants on protein
stability by overexpressing FLAG-tagged WT and mutant MYMK
alleles in HeLa cells. By western blot, WT but no mutant protein
of the expected band size was visible in the soluble fraction after
24 h, despite comparable transfection levels (Supplementary
Fig. 5a,b), suggesting that the mutant alleles are unstable and
degrade and/or aggregate, similar to other mutant membrane
proteins23. We found, however, that immunostaining with a
FLAG antibody revealed a low percentage of M1 and M5
transfected protein at the membrane compared to WT. Notably,
there was no M2, M3 or M4 protein at the membrane, and
transfected M2, M3, M4, and M5 proteins formed cytoplasmic
aggregates (Supplementary Fig. 5c,d).
Based on these data, we next asked whether M1 and M5
fusogenic activity remained intact by exploiting the observation
that ectopic overexpression of WT mouse or human Mymk/
MYMK in fibroblasts leads to fibroblast fusion with C2C12
myoblasts11,18. Indeed, fibroblast overexpression of FLAG-tagged
human MYMK M1 or M5 constructs induced fusion with C2C12
cells, supporting the hypothesis that, despite lower expression
level, they retain residual function. Moreover the M1 allele that is
reported as homozygous in one individual in the ExAC database
had similar fusion as WT, while M5 had reduced fusion. By
contrast, overexpression of M2, M3 or M4 constructs resulted in
no fusogenic activity, supporting these as null alleles (Fig. 3a–c).
Primary myoblasts were available from individual 2, who is
heterozygous for the M1 and M2 alleles. We observed no
difference in the capability of his CFZS mutant cells to
differentiate compared to control myoblasts (Fig. 3d). Following
differentiation, however, there was a significant difference in the
fusion index, with a higher percentage of singly-nucleated relative
to multinucleated cells in CFZS compared to control myoblasts
(Fig. 3e). The differentiated CFZS-derived myoblasts also
appeared hypotrophic, with reduced cell diameter and elongated
cytoplasm compared to the control (Fig. 3f,g). While normal
variability exists among human-derived myoblasts from even a
single affected individual, the reduced fusion and hypotrophy of
CFZS-mutant myoblasts, while not as severe, parallels the
findings in murine Mymk / myoblasts where no fusion
occurs11.
MymkinsT/insT zebrafish lack fast-twitch myoblast fusion. To
confirm pathogenicity and determine if the consequences of null
and hypomorphic MYMK alleles could be distinguished in vivo,
we modelled CFZS variants in zebrafish. Unlike human and
mouse, in which both type I slow-twitch and type II fast-twitch
progenitors fuse to form multinucleated syncytia, zebrafish slow-
twitch muscle progenitors do not fuse. Moreover, the relative
proportions and organization of zebrafish slow- and fast-twitch
fibers change over development and are spatially separated, aiding
in their analysis24. Consistent with its role in muscle fusion,
zebrafish mymk is exclusively expressed in multinucleated fast-
twitch fibers13, whose differentiation and fusion begins after
adaxial cell migration and is completed around 24 h post
fertilization (hpf)25. Knockdown of mymk in zebrafish13 and
Figure 2 | Clinical and radiological and pathological features of MYMK-CFZS. (a) Front (top) and profile (bottom) facial photos of individuals (Ind.) 1–8
highlight facial weakness with flattened nasolabial folds, thin elongated face, midface hypoplasia, prominent nose, micro/retrognathia, and in some, low-set
ears (also lagophthalmos on attempted lid closure, Ind. 8, top). (b) Map of left thigh muscles: vastus lateralis (vl), black; vastus medialis (vm), orange;
rectus femoris (rf), light green; sartorius (sa), yellow; adductor longus (al), dark green; adductor magnus (am), light blue; gracilis (g), pink; semitendinosus
(st), grey; gluteus maximus (gm), purple. Right: left thigh control MRI with sa and am indicated by yellow and blue arrow, respectively. (c) Left thigh MRIs
of Ind. 2, 3, 6, and 7 at ages 37, 19, 7.5, and 7 years, respectively, reveal variable muscle involvement with disproportionate atrophy and fatty infiltration of
the sa (yellow arrows) and am (blue arrows). (d) Compared to control quadriceps (left) Ind. 2 quadriceps biopsy (right, vastus lateralis) shows variable
fiber size (top, hematoxylin and eosin (H&E)), atrophic/hypotrophic type-I fibers (middle, slow myosin heavy chain (MHC), red), hypertrophic type-II
fibers (bottom, fast MHC, red). Scattered type IIc fibers (slow and fast MHC double-positive) were present in the control (shown here) and Ind. 2. Laminin
(green). Scale bar, 50mm. (e) Relative type-I (dashed lines) and type-II (solid lines) myofiber size frequency in control (blue), Ind. 2 (red). (f–i) Ind. 2
versus averaged cohorts of adolescent and young adult male controls (vastus lateralis, age 16–28, n¼ 383)19–22 revealed: (f) significantly increased type II
fiber cross-sectional area of 17,077±4770mm2, which is 330% of measured (4,842±1,288mm2) and reported controls and corresponding type II fiber
minimum Feret diameters of 185% of controls (type I/type II: 60±31/122±21mm versus 57±16/66±11 mm); (g) significantly reduced myofibers per
mm2, and (h) increased type-I fiber proportion (60%), but (i) only slightly decreased overall cross-sectional area composition of type I versus type II fibers
(average fiber area relative composition), consistent with a compensatory response. Significance of fiber size (cross-sectional area and minimum Feret
diameter) and number and nuclei number were assessed with Student’s t-tests and analysis of variance (ANOVA). Mean±s.d.; ***Po0.0001. See also
Supplemental Figs 2, 3.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16077 ARTICLE
NATURE COMMUNICATIONS | 8:16077 | DOI: 10.1038/ncomms16077 | www.nature.com/naturecommunications 5
chick12 myoblasts were reported to produce a fusion defect
similar to that in Mymk / mice. We recapitulated a similar
muscle fusion phenotype by the injection into zebrafish of a
splice-blocking and three translation-blocking morpholinos
(Supplementary Fig. 6). The muscle fusion defects following
morpholino knockdown were incomplete and variable, however,
and thus we employed CRISPR-Cas9 technology to generate a
germline loss-of-function mymk fish line.
We generated a mutant mymk zebrafish line harbouring a
single thymidine insertion in exon 3 (c.434insT; p.Val106Cytf-
sTer33; Fig. 1c). F2 mymkinsT/insT embryos lacked fast-twitch
myoblast fusion at 24 h.p.f. (Fig. 4a). By 48 h.p.f., the nuclei of the
unfused myofibers aligned fully at the center of each myotome, in
contrast to the random-appearing distribution of WT myonuclei
(Fig. 4b, Supplementary Video). This is the same phenotype
reported recently in two other truncating loss-of-function mymk
zebrafish alleles14, and is a similar but far more striking and
penetrant phenotype than that observed in morpholino-treated
embryos (Supplementary Fig. 6). As predicted, loss of mymk
function did not alter the organization of slow-twitch
myofibers, as they do not fuse in WT teleosts (Supplementary
Fig. 7d).
In contrast to Mymk / mice that do not survive, and
consistent with the two previously reported truncating alleles14,
mymkinsT/insT zebrafish were viable, likely because of the residual
function of the slow-twitch mononucleated myofibers
(Supplementary Fig. 7f). Larval and early juvenile mymkinsT/insT
fish were macroscopically indistinguishable from their
heterozygous and WT siblings. By contrast, adult fish were
small and had developed craniofacial deformities (Fig. 4c–e).
Microscopic examination of their fast-twitch musculature
revealed variably-sized hypotrophic fibers with variable degrees
of fatty infiltration compared to their WT siblings (Fig. 4f).
Heterozygous mymkinsT/wt embryos and adults appeared normal.
A similar mutant phenotype was observed in adult F0 fish
injected with a guide targeting exon 5 of mymk, confirming that
this later-onset phenotype was dependent on loss of mymk
function.
Table 1 | Clinical features of CFZS individuals.
Individual ID 1 2 3 4 5 6 7 8
Sex F M F M F F F F
Age (years) Died -37 37 19 1.3 11 7.5 7 28
Geographic location USA USA NZ NZ USA USA USA Brazil
Racial origin White White White White White White White White, Indian,
African
Site of examination Utah NIH CC Auckland Auckland NIH CC NIH CC NIH CC Brazilia
MYMK variant 1 M1 M1 M1 M1 M1 M1 M1 M5
MYMK variant 2 M2 M2 M3 M3 M3 M3 M4 M5
Phenotype %
Facial weakness þ þ þ þ þ þ þ þ 100
Upturned/broad nasal tip þ þ þ þ þ þ þ þ 100
Micro/retrognathia þ þ þ þ þ þ þ þ 100
No abducens nerve
palsy* þ þ þ þ þ þ þ þ 100
Normal cognition þ þ þ þ þ þ þ þ 100
Delayed motor
milestones þ þ þ þ þ þ þ þ / 100
Generalized muscle
hypoplasia þ þ þ þ þ þ þ þ 100
Congenital contractures þ þ þ þ Talipes  4, 5th finger 4, 5th finger 87
Growth failure þ þ þ þ þ þ þ  87
Feeding problems þ þ þ þ þ þ þ  87
Ptosis þ þ þ  þ  þ þ 75
Palate high/cleft þ /Cleft þ / Cleft   þ þ þ þ 75
Gastro/jejunostomy  þ þ þ þ þ   62
Thin tubular neck þ  þ  þ  þ þ 62
Pectoralis hypoplasia þ þ   þ  þ þ 62
Hypoglossia þ þ  þ   þ  50
Scoliosis þ þ    þ  þ 50
Pulmonary hypertension þ þ       25
Cryptorchidism (M) NA þ NA þ NA NA NA NA 100
Clinical score 17/18 18/19 13/18 13/19 15/18 12/18 15/18 13/18
Laboratory testing
CPK (IU/L) N 589
(o308)
NA NA 360
(o149)
282
(o149)
N 543
(o165)
67
EMG Myopathic Myopathic** NA NA Myopathic NA NA Myopathic 100
Muscle MRI NA  z NA    NA 100
Brain MRI NA N NA NA N N N NA 100
Total score 18/20 22/23 14/19 13/19 19/22 15/21 17/21 15/20
F, female; M, male; NIH CC, National Institutes of Health Clinical Center; NA: not available; NZ, New Zealand; USA, United States of America; yrs, years.
M1: c.271C4A, p.P91T. M2: c.553T4C, p.C185R. M3: c.298G4A, p.G100S. M4: c.2T4A,p.0?. M5: c.461T4C, p.I154T. %, percentage of the affected individuals with this sign or symptom. Phenotype.
þ , present;  , absent; * individuals can have minimal limitations of eye movement in extreme positions of gaze; Muscle MRI: () fatty infiltration/hypoplasia of the paraspinal, gluteus maximus,
adductor magnus and sartorius muscles in the thigh. (z) Individual from NZ had isolated sartorius involvement. N: normal or within normal limits. **EMG of individual 2 of the right distal leg (TA, tibialis
anterior) and right proximal arm (triceps) revealed short duration motor units and early recruitment, and quantitative motor unit analysis (QMUAP) had a short mean duration; EMG of the TA, triceps,
and right orbicularis oris revealed no abnormal spontaneous activity.
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Figure 3 | CFZ mutations cause impaired fusion in ectopic expressing cell lines and patient derived cell lines. (a–c) Fibroblast-myoblast cell-cell
fusion experiments: (a) Schematic of heterologous cell–cell fusion system. Fibroblasts were co-infected with GFP plasmid and FLAG-tagged WTor CFZS-
mutant MYMK construct, co-cultured with C2C12 myoblasts for 4 DIV, and immunostained with myosin antibody, a myocyte marker. If fibroblast-myoblast
fusion occurs, chimeric myotubes appear yellow/orange from colocalization of GFP (green, fibroblast origin) and myosin (red, myoblast origin). (b)
Fibroblasts co-infected with mouse or human WT MYMK-FLAG constructs and GFP fuse with C2C12 cells. Hypomorphic CFZ mutations M1 (p. P91T) and
M5 (p. I154T) retain fusogenic activity, while fibroblasts infected with empty vector or null CFZ mutations M2-M4 do not. White arrows indicate GFPþ
myosinþ yellow fused myotubes, whereas white arrowheads highlight unfused myosinþ myocytes. (c) Quantification of heterologous fusion between
infected fibroblasts and C2C12 cells. The number of GFP-positive myotubes was counted and normalized by the total number of Myo32 positive myotubes.
(d–g) CFZS primary myoblasts fusion experiments: (d) Differentiation index, calculated as number of nuclei in myosin positive cells divided by the total
number of nuclei in all cells per field, shows no difference between control and Ind. 2 primary myoblast cell lines. (e) Quantifications of the number of
nuclei in myosinþ cells reveal a significant increase in single nucleated cells and decrease in multinucleated cells in Ind. 2 derived cells compared to control.
(f) The cell diameter of Ind. 2 myoblasts is significantly reduced compared to control myoblasts (n¼45). (g) Image of control myoblasts (left) reveals
greater width, more cytoplasm, and more nuclei per fiber (white arrow) than Ind. 2 myoblasts (right—white arrowhead) at 7 DIV post differentiation. Blue:
DAPI stain of nuclei. Red: myosin heavy chain A4.1025 antibody. Analyses of fusion assay and differentiated myoblasts were each performed on at least 6
and 10 random fields per experiment, respectively, and 3 independent experiments. Statistical analyses in: (c) calculated by one way ANOVA with
Bonferroni correction for multiple testing and shown as comparison to the empty vector (EV); (d–f) using two-tailed Student’s unpaired t test.
Mean±s.e.m.; **Po0.001; ns, not significant. Scale bars in b,g, 50mm. See also Supplementary Fig. 5.
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Figure 4 | mymkinsT/insT zebrafish embryos lack fast-twitch myoblast fusion and adults have CFZS-like myopathic features. (a) 24 h.p.f. embryos
stained with 488-conjugated phalloidin (white) and DAPI (red) to label the forming myofibers and nuclei, respectively. WTmymkwt/wt embryo myofibers
are multinucleated, while mymkinsT/insT embryo myofibers elongate and differentiate, but fail to fuse. (b) Upper panel: 48 h.p.f. embryos stained with DAPI
show the distribution of myonuclei in fused mymkwt/wt (left) and unfused (right) mymkinsT/insT fast-twitch myofibers. Compared to the random appearance
of WTmyonuclei, the single nuclei in unfused mymkinsT/insTmyofibers pathologically align at the center, equidistant between two myosepta. Lower panel:
Merged images showing phalloidin (red), DAPI (white) and F59 (green, anti-myosin heavy chain) confirm that affected myofibers are fast-twitch fibers
because they do not express F59, a slow-twitch cellular marker in zebrafish. (c) A 6-month-old male mymkwt/wt zebrafish (top) compared to an age- and
sex-matched tmem8cinsT/insT fish (bottom). Male and female mutant zebrafish are small and have a flattened/retrognathic jaw (right, indicated by dotted
line and black arrowhead) not appreciated during larval and early juvenile stages. By 3 months of age, jaw weakness prohibits mymkinsT/insT zebrafish from
fully closing their mouths. (d,e) Adult mymkinsT/insT zebrafish (n¼ 3) are significantly shorter (d) and weigh less (e) than age and sex-matched WTsiblings
(n¼ 7). (f) Hematoxylin-Eosin (H&E) staining of caudal transverse sections of WT (top) and mymkisnT/insT (bottom) of 6-month-old male zebrafish siblings
at three magnifications. Zebrafish mymk-expressing fast-twitch myofibers are located centrally, while mymk-negative slow-twitch myofibers are located
near the body wall and stain slightly darker with H&E. The mutant fish have reduced body width (compare the red line extending from the dorsal artery to
the body wall in WT versus mutant fish in left photos), and fat infiltration (thick black arrows, middle photo) that is absent in the WT fish. Fast-twitch
myofibers appear smaller compared to WT (right). Statistics by two-tailed Student’s unpaired t-test; mean±s.e.m.; **Po0.002. Scale bars, (a,b) main
images 50mm, insets 10mm. (f) left and center panels 500mm, right panels 50mm. See also Supplementary Figs 6,7 and Supplementary Video.
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WT or hypomorphicMYMK mRNA rescues mymkinsT/insT fish.
We used the mymkinsT/insT loss-of-function zebrafish line to
confirm the pathogenicity of the CFZS alleles in vivo and their
function as null or hypomorphic alleles. We injected WT or
mutant human MYMK mRNA and membrane bound mCherry
fluorescent protein26 into mymkinsT/insT embryos, and visualized
myonuclear alignment at 48 hpf to evaluate the ability of the
injected mRNA to rescue the myoblast fusion defect (Fig. 5a). By
blinded qualitative analysis, injection of WT MYMK mRNA
resulted in myonuclei distributed in a random- or near-random-
appearing pattern in 80% of embryos, thus rescuing the
mymkinsT/insT phenotype. By contrast, injection of M2 or M3
MYMK mRNA resulted in no rescue of the mymkinsT/insT
phenotype, and was indistinguishable from injection of
mCherry alone, while injection of M1 or M5 MYMK mRNA
resulted in an intermediate level of rescue (Fig. 5a–c). We
obtained similar but less penetrant results when we co-injected
WT or mutant mRNA together with a transcription-blocking
morpholino into WT embryos (Supplementary Fig. 6d,f,g).
To quantify the rescue phenotypes, we measured the distances
between myonuclei in mymkwt/wt embryos, mymkinsT/insT
embryos, and mymkinsT/insT embryos injected with WT-, M1-,
M2-, M3-, or M5- MYMK human mRNA. For each injected
allele, we then calculated for each nucleus the frequency
distribution of all nuclei within a 5 mm to 80 mm distance
(Fig. 5d). mymkwt/wt embryos, and mymkinsT/insT embryos
injected with WT mRNA, had a random distribution of
myonuclei, while mymkinsT/insT did not (Fig. 5d). The distribution
of nuclei in mymkinsT/insT embryos injected with M2- or M3-
mutant mRNA were not significantly different than mymkinsT/insT
alone, confirming these as null alleles (Fig. 5d–h). By contrast,
mymkinsT/insT embryos injected with M1 or M5 resulted in
distributions intermediate between mymkwt/wt and mymkinsT/insT,
consistent with hypomorphic function (Fig. 5g,h). Moreover,
while not significantly different from one another, the distribu-
tion following injection of M1-mRNA was more similar to
mymkwt/wt, while the distribution following injection of M5-
mRNA was more similar to mymkinsT/insT injected with M2- or
M3-mRNA. These data support the pathogenicity of the MYMK
alleles and their null or hypomorphic status. They also suggest
greater residual mymk activity of M1 over the other disease
alleles, consistent with the in vitro fusion assay results and with
the presence of homozygous M1 in the ExAC database in one
individual with no declared phenotype.
Discussion
We demonstrate that recessive mutations in MYMK cause CFZS
through a combination of one hypomorphic and one null allele,
or two hypomorphic alleles, which reduce MYMK function and
myoblast fusion below a threshold but not to zero
(Supplementary Fig. 4). Despite the presence of the hypomorphic
M1 allele at a very low frequency in the ExAC database in the
heterozygous state and in one individual of unknown clinical
status in the homozygous state, both our in vitro and in vivo data
support its pathogenicity. It does, however, have the highest level
of residual MYMK activity among the mutant alleles. Thus, it will
be of interest to identify and phenotype individuals who are
homozygous for the M1 or compound heterozygous for the M1
and M5 alleles to define the threshold of MYMK activity below
which one manifests the CFZS phenotype. We also anticipate
that, similar to Mymk / mice11, two null alleles will result in
absence of muscle and be incompatible with human life
(Supplementary Fig. 4).
The combined clinical, imaging, and muscle biopsy findings in
CFZS define a distinct disorder. Significant facial weakness and
Robin sequence, minimal limitation of horizontal end-gaze, only
mild axial and appendicular weakness, and CFTD on muscle
biopsy distinguishes CFZS from most other congenital myopa-
thies. CFZS may have greatest clinical overlap with Native
American myopathy resulting from STAC3 mutations27,28,
although the absence of malignant hyperthermia in CFZS and
possibly different muscle pathologies distinguish them. The
characteristic distribution of fatty infiltration/atrophy on muscle
imaging in CFZS is similar to that reported in SEPN1 CFTD29, in
which respiratory muscle weakness, scoliosis, and impaired
muscle regeneration are present, but facial weakness is not
prominent30,31. CFZS pathophysiology may most closely
resemble EMARDD (early onset myopathy, areflexia, respiratory
distress, and dysphagia), which results from MEGF10 mutations
that appear to reduce myocyte proliferation, differentiation, and
fusion32–34. By contrast, the ability to almost fully abduct the eyes
in CFZS permits its distinction from Moebius syndrome, in which
abduction limitation is complete or nearly complete8. Finally, as
anticipated2,6, normal cognition, absence of seizures and abducens
nerve palsy, and normal brain and brainstem imaging shared by
the MYMK-CFZS individuals in this report suggest that many
cases previously reported to be CFZS likely represent different
disease entities2–7.
While the current CFZ muscle pathology fits best within the
category of CFTD35,36, the type II hypertrophy is greater than
typically reported37,38. Our data also support the appearance of
more distinctive muscle pathology and an increase in fatty
infiltration of specific muscle groups over time, potentially
correlating with slow progression of weakness and adult-onset
restrictive pulmonary disease. Thus, additional longitudinal
clinical data coupled with analyses of serial biopsies that target
Figure 5 | Ectopic expression of MYMK-WTand -hypomorphic alleles can fully or partially rescue the mymkinsT/insT fusion phenotype. (a) Approach to
evaluate rescue of mymkinsT/insT 48 h.p.f. embryo fusion phenotype following co-injection of WT or mutant human MYMK mRNA. Nuclear dispersion is
qualitatively stated to be low (no rescue), minimal (slight rescue), moderate (partial rescue), or high (rescue). (b) Optical sections of laterally mounted
48 hpf mymkwt/wt embryo injected with mCherry, and six mymkinsT/insT embryos injected as per a. WT-, M1-, M5-MYMK mRNA injected embryos show
partial rescue. M2-, M3-, and mCherry alone do not. Red: membrane bound mCherry. White: DAPI. Scale bar¼ 50mm. (c) Qualitative analysis of nuclear
organization of embryos in b according to colour key in a. (d) Digitized images of the distribution of randomly generated non-overlapping xy positions (left),
mymkwt/wt myonuclei (middle), mymkinsT/insTmyonuclei (right); left-right arrow d denotes distance between two nuclei; circles a, b, c areB10, 25, 50mm
from center nucleus, respectively. (e) Frequency of distances from each nucleus to all others. 2D random (grey), mymkwt/wt (black) and mymkinsT/insTþWT
mRNA (green) have the same trend, while mymkinsT/insT (red) exhibits differences at distances a, b, c (circles in d). Increased frequency at distance a
reflects the increased number of near neighbors. Decreased frequency at distance b reflects the lack of nuclei between the rows of aligned nuclei in
mymkinsT/insTembryos. (f) mymkinsT/insTembryos injected with mutantMYMKmRNAM2 (yellow) or M3 (orange) have normalized frequencies most similar
to mymkinsT/insT (red dashed line) versus mymkwt/wt (black dashed line), consistent with lack of rescue. (g) mymkinsT/insT embryos injected with mutant
MYMK mRNA M5 (turquoise) or M1 (blue) have normalized frequencies that fall between mymkinsT/insT (red dashed line) versus mymkwt/wt (black dashed
line), consistent with partial rescue. Shaded bands¼±SEM. (h) Two sample analyses for statistical significance (Kolmogorov-Smirnov) between couples
of distributions in regions a, b. Top: Statistics for nuclei that fall in a distance range of 5mmodo10mm (circle a). Bottom: Statistics for nuclei that fall in a
distance range of 18mmodo28mm (circle b). Grey box: NS (PKS40.05); Yellow box: *0.01oPKSo0.05; Red box: **PKSo0.01. See also Supplementary Figs 6,7.
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more significantly and specifically affected muscle groups may
lead to the recategorization of this disorder.
The congenital facial weakness and Robin sequence of CFZS
highlight the selective vulnerability of specific muscle groups to
reduced levels of MYMK, and the interplay between muscle and
bone development. Compared to other skeletal muscles, cranio-
facial muscles use unique developmental pathways39 and have
distinct molecular compositions and combinations of fiber
types40 that may, in part, account for their vulnerability.
Muscle is known to influence bone development and, like
CFZS, other congenital myopathies with significant facial
weakness are often accompanied by secondary retrognathia,
palatal defects, and facial dysmorphisms1,41. Similarly, Myf5 /
 :MyoD / mice are born without muscles, including jaw and
tongue muscles, and have secondary retrognathia and cleft
palate42.
While complete loss of Mymk in mice is perinatal lethal,
zebrafish live and phenotypes only become evident at a late
juvenile age. Notably, the relative number and distribution of fast-
and slow-twitch muscle fibers in zebrafish change during
maturation, and these fiber type changes are believed to be
necessary for optimization of swimming ability and feeding
behaviours as the fish grow and mature from larvae into
adults43,44. Specifically in cranial musculature, including in the
adductor mandibulae muscle, there is a gradual increase in the
proportion of fast-twitch fibers during larval and juvenile stages,
followed by the preferential growth and expansion of fast-twitch
muscle beds during the juvenile to adult transition43. Fast-twitch
but not slow-twitch myoblasts fuse in zebrafish, and mymk is
expressed only in fast-twitch myoblasts. Thus, failure of fusion of
the fast-twitch fibers during this normal fiber type adaptation,
coupled with reduced regenerative capacity suggested by
progressive fatty infiltration of muscle, may explain the onset of
the mymkinsT/insT phenotype in the late juvenile stage, and the
appearance of micrognathia in adult zebrafish.
While both type I and type II human striated muscle fibers fuse
during muscle development, it remains to be determined if
different muscles and/or different fiber types require different
levels of fusion and/or express different levels ofMYMK, resulting
in selective vulnerability to a reduction in functional MYMK
protein. Future studies should both clarify this selective vulner-
ability and more clearly define the CFZS clinical course. Finally,
the ability to genetically rescue the mutant phenotype in zebrafish
lends hope for future therapies that restore MYMK function in
muscle and lessen any potentially progressive features of this
disorder.
Methods
Subjects. Research participants were enrolled under protocols approved by the
Institutional Review Boards of the appropriate participating Institutions: University
of Utah, Salt Lake City, UT; University of Otago, Dunedin, New Zealand; Boston
Children’s Hospital, Boston, MA; National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD; Johns Hopkins Medicine, Baltimore,
MD; Icahn School of Medicine at Mount Sinai, New York, NY. Studies were
performed in compliance with US 45.CFR.46. Adult participants and guardians of
children provided written informed consent for participation and for publication of
identifying photographs. Four affected individuals and their carrier parent(s) were
re-examined at the NIH Clinical Research Center under protocol 14-HG-0055
‘Study on Moebius syndrome and other congenital facial weakness disorders’
(ClinicalTrials.gov identifier: NCT02055248). Authors and referring physicians
submitted clinical data for the other four affected individuals.
Exome sequencing and analysis. Exome analysis of family 1. Whole exome
sequencing was carried out on blood DNA samples isolated from the proband,
affected sister, unaffected brother and parents. Exome capture and DNA
sequencing were performed at the University of Utah High Throughput
Genomics Core Facility using the Agilent SureSelect Human Exon V5 kit (Agilent
Technologies Inc.) and the Illumina HiSeq DNA sequencing system. Paired-end
raw sequencing data from each individual were aligned to the reference human
genome (GRCh37) with two alignment programs, BWA45 and Novoalign
(www.novocraft.com). Using the software package SAMtools46, the aligned
sequencing reads were converted and merged to sorted and indexed BAM files. The
standard GATK pipeline (https://www.broadinstitute.org/gatk/) was then used to
call sequence variants. Functional annotation and filtering of sequence variants
were performed with ANNOVAR47 and with the DNA-Seq analysis module of
Golden Helix SVS (Golden Helix Inc.). Variants were classified with respect to
location (exonic, intronic, splice site, 50-UTR, 30-UTR, upstream, downstream, or
intergenic), exonic functions (nonsynonymous, synonymous, stop, frameshift
insertion/deletion, etc.), minor allele frequencies (MAF) reported in various public
databases (http://www.1000genomes.org/, http://evs.gs.washington.edu/EVS/, and
http://exac.broadinstitute.org/), and the dbNSFP functional prediction of
nonsynonymous amino acid changes (https://sites.google.com/site/jpopgen/
dbNSFP). Segregation of rare (MAFo0.01) functional candidate variants was
analysed in the family using recessive and compound heterozygosity inheritance
models.
Exome analysis of family 2. Whole exome sequencing was carried out on blood
DNA samples isolated from both affected sibs and their parents. Exome capture
and DNA sequencing was performed by New Zealand Genomics Ltd using the
Illumina Nextera Rapid Capture Exome Kit and Illumina HiSeq 2500 DNA
sequencing platform. Paired-end raw sequencing data for each individual were
aligned to the reference human genome (GRCh37) with BWA and further
processed according to GATK Best Practice Guidelines with HaplotypeCaller as the
variant caller. Gene context annotation and dbNSFP data was added using SnpEff48
and allele frequency information from 1000 genomes, ESP6500 and ExAC using
GATK AnnotateVariants. Filtering was undertaken using SnpSift and GATK
SelectVariants. Variants were classified and segregation analysed as described for
Family 1.
Exome analysis of family 3. DNA from the proband was extracted from a blood
sample using the Puregene kit (Qiagen, Valencia, CA) while DNA from the
remaining family members was extracted from saliva samples using purifier
solution (DNA Genotek, Canada). DNA quality was ascertained and quantified
using Tapestation (Agilent Technologies, Santa Clara, CA) and 3 mg of high quality
DNA were used for exome capture and sequencing. Exome capture was performed
at the Ocular Genomics Institute (OGI) at Massachusetts Eye and Ear Institute
using Agilent SureSelect Human Exome V4 for the proband and Agilent V5þUTR
kit for the affected sibling and parents. Captured products were sequenced using
one third of a lane of Illumina HiSeq 2000 Next-Generation Sequencing system
using v2.5 SBS chemistry; average flow cell lane cluster densities were
B800Kmm 2 and 94% average 10 coverage of the target exome. Raw reads
were aligned using Best Practice pipeline developed at the Broad Institute and
called variants were annotated and filtered using the xBrowse online tool (http://
atgu.mgh.harvard.edu/xbrowse). Variants here harmonized with an internal
database of 375 control exome sequences generated from sequencing data obtained
by the Analytical and Translational Genetic Unit at Mass General Hospital. Finally,
variants were filtered by passing the PASS quality filter present in GATK.
Remaining variants were then classified and segregation analysed as described for
Family 1.
MYMK sequence analysis of research cohorts. DNA from 4300 participants
diagnosed with CFZS, Moebius syndrome, or other forms of syndromic congenital
facial weakness enrolled at Boston Children’s Hospital, Icahn School of Medicine at
Mount Sinai, Baylor-Hopkins Center for Mendelian Genomics, or the NIH Clinical
Research Center were Sanger sequenced for all coding exons and intron-exon
boundaries of MYMK using ABI 377 DNA sequencer (BCH IDDRC Molecular
Genetics Core Facility), ABI 3730XL DNA analyser (Genewiz, Inc. and ACGT,
Inc.), or ABI 3730 (Applied Biosystems, Life Technologies, Carlsbad, Calif., USA).
Primer sequences are reported in Supplementary Table 3. Sequence data were
analysed and compared with normal control and reference sequence (GRCh37/
hg19) for variants using Sequencher (Gene Codes Corporation), Mutation Surveyor
(SoftGenetics), and/or CodonCode Aligner 3.6.1. If a mutation were identified in
the proband, participating family members were screened for its presence or
absence.
Haplotype construction. Highly heterozygous SNPs within an 80 kb region sur-
rounding MYMK and dinucleotide microsatellites markers (D9S2135 and
D9S1793) proximal to the gene identified in UCSC Genome Browser (https://
genome.ucsc.edu), and an unannotated dinucleotide sequence (MymkMicro) in
MYMK intronic sequence, were screened by direct Sanger sequencing in all rele-
vant affected individuals and their parents. Primers sequences are reported in
Supplementary Table 3.
Electromyogram/nerve conduction studies. Needle EMG studies of right distal
leg (tibialis anterior), right proximal arm (triceps branchii) and perioral muscles
(orbicularis ori) were performed using a concentric needle with spontaneous and
motor unit activity recorded according to standard methodology. Nerve conduc-
tion studies were performed primarily on the median and sural sensory nerves and
the median and peroneal motor nerves. Measurements used standard methodology
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with a Nicolet Viking Select machine (Cardinal Health, Dublin, OH) and were
compared to department-based normative values49.
Brain magnetic resonance imaging (MRI). Brain MRI was performed on a 3T
Achieva Philips scanner with 8-channel head coil at the National Institutes of
Health Clinical Radiology. Multiple MRI sequences were acquired: T1 weighted
(0.94 0.94 1mm), T2 weighted (0.86 0.86 3.2mm), axial fluid attenuated
inversion recovery (FLAIR) (0.86 0.86 3.2mm), and high resolution brainstem
images (0.31 0.31 0.4mm).
Muscle magnetic resonance imaging. Muscle magnetic resonance imaging
(MRI) was performed using conventional T1 weighted spin echo on a 1.5-T Aera
Siemens or Achieva Phillips, or 3.0-T Verio Siemens system. Non-contrast images
were obtained in the axial plane of the pelvis, thighs and lower legs. Slices were
7–8mm thick and the gap between slices varied from 6 to 10mm. Scans were
assessed for abnormal muscle bulk and for abnormal signal intensity within the
different muscles.
Muscle biopsies. Frozen muscle tissue from a right quadriceps (vastus lateralis)
muscle biopsy from individual 2 (15 years old at the time of biopsy; obtained for
clinical indications) was sent to the Engle Laboratory at Boston Children’s Hospital
and re-evaluated with new sections and stains. For comparison, a total of 184 de-
identified muscle biopsy cases at Boston Children’s Hospital were reviewed for
diagnoses of minimal abnormalities, and similar age and sex to individual 2. From
these, nine cases were cut, stained, imaged and compared. Section thickness in
Fig. 2d is 10 mm (all H&E and control MHC) and 12 mm (Ind. 2 MHC). Quanti-
fication was performed on a representative case that appeared to most closely
match published findings for the vastus lateralis muscle at this age (‘control’
quadriceps biopsy from an active 14.5-year-old male, diagnosed as ‘skeletal muscle
with rare atrophic fibers,’ without other diagnostic abnormalities). For nuclei
counts, a second quadriceps biopsy from a 13-year-old male diagnosed as ‘skeletal
muscle with mild variation in fiber size’ was quantified as ‘Control 2’). To compare
CFZS findings with a broader cross-section of individuals, we evaluated published
data of vastus lateralis measurements (relative fiber type composition, fiber type
cross-sectional area, and percentage fiber type areas) from four cohorts of young
men (age 16–28, n¼ 383 individuals) from the literature: cohort-1 (n¼ 95,
21.1±2.4 years)19, cohort-2 (n¼ 215, 24±4 years)20, cohort-3 (n¼ 55, 16±0
years)21 , and cohort-4 (n¼ 18, 17±1 years)22.
The myofiber (fiber) cross-sectional area was calculated from the entire biopsy
from each individual, including 3569 fibers from individual 2, and 609 fibers from
the control individual. No blinding was possible due to the characteristic
phenotype of the patient muscle biopsy. Fiber number and nuclei number were
measured from three distinct regions from each biopsy, normalized to number per
mm 2, based on the areas measured, and the means and standard deviations were
calculated in Microsoft Excel. Relative fiber type composition (type I fiber number/
total fiber number) and percentage fiber type area (type I relative fiber type
compositionmean type I area/(type I relative fiber type compositionmean
type I areaþ type II relative fiber type compositionmean type II area)) were
calculated for each area of the biopsy. Image alignments were performed in Adobe
Photoshop. Fiber cross-sectional area and minimum Feret diameter were measured
using Image J (1 pixel in raw images¼ 0.3467 mm). Fibers were binned in 500 mm2
increments for histogram generation. For comparative cohort 4 (ref. 22),
approximate fiber area was calculated as the square of the reported diameters
(which were the mean of the maximum and minimum Feret diameters). Type II A
and type II B fiber sizes were combined into a single average Type II fiber size for
each cohort. All other measurements from cohorts 1–4 are presented directly as
reported19–22. Significance of fiber size (cross-sectional area and minimum Feret
diameter) and number and nuclei number were assessed with Student’s t-tests and
analysis of variance (ANOVA) in Microsoft Excel. Graphs for the muscle biopsy
analysis were generated in Microsoft Excel with mean±s.d. reported. A P-
valueo0.05 was considered significant.
Human primary myoblast cultures. A needle biopsy was obtained from the rectus
femoris muscle of individual 2 at 37 years of age using a percutaneous needle under
NIH protocol 00-N-0043 ‘Clinical and Molecular Manifestations of Inherited
Neurological Disorders’ (ClinicalTrials.gov identifier: NCT00004568). Control
primary myoblasts were obtained from a hamstring open biopsy of a 30-year-old
healthy white non-Hispanic female and generously provided by Louis Kunkel
(Boston Children’s Hospital IRB protocol #03-12-205R). Primary myoblasts were
isolated from biopsy explants using the EuroBioBank protocol. In brief, muscle
explants were isolated from adjacent connective and fatty tissue using a dissecting
scope. Muscle explants were then plated on T25 flasks and allowed to attach. Small
amounts of proliferating medium (DMEM supplemented with 20% FBS, L-gluta-
mine, 1 penicillin-streptomycin, insulin (10 mgml 1), human basic fibroblast
growth factor (25 ngml 1)) were added and the myoblasts were allowed to grow
and proliferate for several days before they were enzymatically detached and plated
separately.
For culture and differentiation, primary myoblasts were grown on 0.1% gelatin-
coated dishes in Skeletal Muscle Cell Growth Media with supplement (PromoCell
GmbH), complemented with 20% Fetal Bovine Serum (FBS), 1 Antibiotic-
Antimycotic (ThermoFisher), 1x Glutamax (ThermoFisher). Cells were passaged
every 48 h. For differentiation into multinucleated myotubes, growth medium was
switched to Skeletal Muscle Cell Differentiation Media with supplements
(PromoCell GmbH), complemented with 2% Horse Serum (HS), 1x Glutamax
and 1x Antibiotic-Antimycotic. Cell culture medium was refreshed every three
days.
C2C12 and HeLa and fibroblast cell cultures. C2C12 cells, 10T1/2 fibroblasts,
and HeLa cells were purchased from American Type Culture Collection and
maintained in DMEM (Sigma) containing 10% heat-inactivated FBS supplemented
with antibiotics. Cells were not re-authenticated and were not tested for myco-
plasma. C2C12 cells were differentiated by switching to media containing 2% heat-
inactivated horse serum and antibiotics. All solutions described as a percentage are
based on vol/vol.
Plasmids. Human MYMK sequence cloned in a pCMV6-Entry vector was pur-
chased from Origene and mutagenized using QuickChange II XL Site-directed
mutagenesis kit (Agilent Technologies) according to the manufacturer’s specifi-
cations and using the following primers:
P91T_F: 50-CTGGCCGACTTCGACGAAACCAAGAGGTCAACATTTG-30 ,
P91T_R: 50-CAAATGTTGACCTCTTGGTTTCGTCGAAGTCGGCCAG-30 .
I154T_F:50- CCGGGGCCTGTCTGCTGGGTGTAGACG-30 , I154T_R: 50-
CGTCTACACCCAGCAGACAGGCCCCGG-30 .
G100S_F: 50-CATTTGTGATGTTCAGCGTCCTGACCATTG-30 , G100S_R:
50-CAATGGTCAGGACGCTGAACATCACAAATG-30 .
C185R_F: 50-CACAGCTTCTACCACCGTGCCCTGGCTATG-30 , C185R_R:
50-CATAGCCAGGGCACGGTGGTAGAAGCTGTG-30 .
Quality and accuracy of the mutagenesis were evaluated by direct capillary
sequencing using primers spanning the T7 promoter. WT human MYMK-FLAG
plasmid and human MYMK-FLAG constructs harbouring the individuals’
mutations were designed and purchased as gBlocks gene fragment (Integrated
DNA Technologies) and cloned into pBabe retroviral vector using EcoRI restriction
site. The FLAG nucleotide sequence was 50-GATTACAAGGATGACGACG
ATAAG-30 , and the signal sequence upstream of FLAG was 50-ATGAAGAC
GATCATCGCCCTGAGCTACATCTTCTGCCTGGTGTTCGCC-30 . These
FLAG-tagged sequences were then subcloned in a pCDNA v3.1 vector for
expression in HeLa cells. For rescue of mymkinsT/insT zebrafish, WT human MYMK
and the mutant plasmids generated as described above were subcloned without the
FLAG sequence in a pCS2þ backbone using XhoI and EcoR1 restriction enzymes.
HeLa cell transfections. HeLa cells were plated on 6-wells plate for protein
extraction or on 0.1% gelatin-coated glass slides in 24-wells plate for immunos-
taining experiments. Each plasmid was co-transfected with minimal amount of
pmaxGFP (Lonza) using Lipofectamine 2000 according to manufacturer
recommendations.
Cell fusion experiments. Platinum E Cells (Cell Biolabs) were plated on a 100-
mm culture dish at a density of 3 106 cells per dish and 24 h later were trans-
fected with ten micrograms of retroviral plasmid DNA coding mutant MYMK and
GFP protein using FuGENE 6 (Roche). Forty-eight hours after transfection, viral
media was collected, passed through a 0.45-mm cellulose filter, and mixed with
Polybrene (Sigma) at a final concentration of 6 mgml 1. For live staining
experiments, 10T1/2 fibroblasts (B50–60% confluent on a 100-mm plate) were
infected with 10ml virus for 18 h. After infection, cells were washed  3 with PBS,
trypsinized, and mixed with C2C12 cells at a 1:1 ratio (3 105 each cell type),
and plated on a 35-mm dish in 10% FBS and DMEM. The following day the cells
were placed in differentiation medium (DMEM with antibiotics and 2%
Horse serum) for four DIV, and then GFP and myosin positive cells were
analysed.
Zebrafish husbandry. All zebrafish experiments were approved by the Boston
Children’s Hospital Institutional Animal Care and Use Committee (IACUC). WT
AB zebrafish strain was maintained according the standard procedure of the
Boston Children’s Hospital Aquatic Resources Program. One male fish was crossed
to two females to obtain enough fertilized eggs for each embryonic experiment.
CRISPR-generated mymkinsT fish were genotyped as described below and separated
in different tanks according to their genotype. Homozygous mutant lines survive
and are capable of self-feeding, but required separation from their heterozygous
and WT siblings as young adults because they could not successfully compete for
food and were at risk of starvation. The tanks housing mymkinsT adult fish required
cleaning once a month to avoid excessive accumulation of food at the bottom of the
tank.
Generation of mymkinsT line. Highly efficient CRISPR target sites for zebrafish
mymk were selected using the browser CHOPCHOP (www.chopchop.c-
bu.uib.no)50,51. Two exon 3 (sgRNA1 and sgRNA2) targets and one exon 5
(sgRNA3) target were selected. sgRNAs were generated by annealing long oligos to
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a Sp6 promoter sequence, followed by in vitro transcription52. To generate loss-of-
function lines, 250 pg of sgRNA and 500 pg of recombinant Cas9 protein (PNA Bio
Inc.) were incubated on ice for 10min and injected into the cytoplasm of one-cell
stage AB embryos as described for morpholino injections. Efficiency of the guide
was evaluated by sequencing 10 of the approximately 100 injected embryos per
clutch for each guide. Successful editing was indicted by multiple nucleotide peaks
4–5 bases 50 to the PAM sequence. Chimeric sequences were identified for 60% of
sgRNA1, 10% of sgRNA2 and 100% for sgRNA3 injected embryos. The low
efficiency of editing for sgRNA2 may be explained by the presence of a SNP in our
AB line located 50 of the guide binding region. SgRNA1 guide was selected to
establish the F0 population because sgRNA3 generated 100% edited embryos in the
homozygous state, and the muscle hypoplasia of the resulting fish would place
them at risk for decreased fertility secondary to impaired swimming and spawning.
F0 embryos generated with the sgRNA1 guide were outcrossed with WT AB
and their offspring (F1) screened for germline transmission of the editing. We
identified three different changes at the level of the cutting site, of which the most
common was an insertion of a T at position c.434, predicted to cause a frame-shift
resulting in 33 ectopic amino acids before a stop codon. Three founders were used
to generate the F2 population, called mymkinsT, used in this study. Genotyping was
performed using Taqman probes (Applied Biosystem) specifically designed to
discriminate between the mutant mymkinsT and WT alleles. Primers used to
generate the guides are as follows: sgRNA1 50-GGGGTGTTGACCGCAGCTG
TGA-30 ; sgRNA2 50-GGCATTTACTCCGGCCCCATCGG-30 ; sgRNA3 50-CGT
GTCTCTGGCCATGTCCT-30 . Zebrafish exon 3 sequencing primers are as follows:
Ex3FRW: 50-TCAAAGTGGCTTAAAATGCTCA-30 ; Ex3RVS: 50-GAGTAGATG
CCGTATCCCAGTC-30 .
Western blot of overexpressed MYMK alleles in HeLa cells. HeLa cells were
collected at 24 h after transfection and lysed using RIPA buffer (ThermoFisher)
supplemented with a cocktail of proteases and phosphatases inhibitors (Thermo-
Fisher). After quantification of the total proteins using BCA assay, 10 mg of total
lysate was loaded on a polyacrylamide gel 4–12% (Invitrogen) in Bis-Tris buffer for
electrophoresis according to the manufacturer’s recommendations. Novex nitro-
cellulose membranes (Invitrogen) were used for transfer. The FLAG-tag signal was
revealed using mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, F9291)
at a final dilution 1:1,000, and anti-beta Actin HRP-conjugated (Abcam, ab20272)
at final dilution of 1:10,000 was used as loading control.
Histochemistry and immunofluorescence. Human muscle biopsy sectioning
(10 mm thick sections) and haematoxylin and eosin (H&E) staining for nuclei
quantification were performed in the histology laboratory in the Department of
Pathology at Boston Children’s Hospital. Clinical diagnostic histochemical staining
(12 mm thick sections) was performed in the Neuropathology laboratory in the
Department of Pathology at Brigham and Women’s Hospital: H&E, Myofibrillar
ATPase at pH 4.3, Myofibrillar ATPase at pH 9.4, NADH diaphorase, Gomori
trichrome, periodic acid-Schiff, and Oil Red O. Immunohistochemical staining (on
12mm thick sections) was performed with the following primary antibodies: mouse:
Pan-MHC (Developmental Studies Hybridoma Bank (DSHB), (A4.1025, 1:200),
Slow-MHC (DSHB, A4.840, 1:100), Fast-MHC Type IIA (DSHB, SC-71, 1:100),
MYH1A (DSHB, F59, 1:20) Embryonic MHC (DSHB, F1.652, supernatant, 1:18),
Myogenin (DSHB, F5D, supernatant, 1:18), Pax7 (DSHB, Pax7, 1:50), Pecam-1/
CD31 (DSHB, P2B1, 1:50), Lymphocyte Common Antigen (LCA)/CD45 (DSHB,
H5A5, 1:50), Vimentin (DSHB, 3CB2, supernatant, 1:44), Desmin (DSHB, D3,
1:100); rabbit: Laminin (Sigma-Aldrich, L9393, 1:1,000). The following secondary
antibodies were used (1:1,000 dilution): goat anti-mouse highly-cross-adsorbed 546
(ThermoFisher, A-11030), goat anti-rabbit 488 (ThermoFisher, A-11008). Muscle
sections were blocked and permeabilized for 2 h at room temperature (RT) with
10% normal goat serum in 0.3% Triton-X and 1X PBS, incubated overnight (ON)
with primary antibodies in blocking solution at 4 C, and stained with secondary
antibodies for 2 h at RT, followed by counter-staining with DAPI (1:10,000) for
5min, and mounting in Fluoromount-G. Imaging was performed on an Olympus
VS120-SL whole slide scanner at 20 magnification.
For myosin staining of primary myoblasts, cells were plated on gelatin-coated
permanox chamber slides (ThermoFisher), washed twice in PBS, and then fixed in
2% PFA in PBS. Cells were permeabilized with PBSþ 0.5% Triton for 10min at RT.
After one hour incubation in blocking solution (2%BSA in PBS), cells were
incubated overnight (ON) with primary antibody anti-myosin heavy chain all
isoform (clone A4.1025, 1:100, DSHB) and then washed for three times with PBS
followed by 1 h incubation with secondary fluorescent anti-mouse conjugated
antibody. After three gentle 10min washes in PBS, cells were incubated with DAPI
for 5min, washed, mounted with Fluoromount G, and imaged using an Olympus
BX51 fluorescent microscope.
For live staining of HeLa cells (non-permeabilized), 24 h after transfection cells
were washed once with ice cold PBS and blocked for 45min in blocking buffer (3%
BSA in PBS) on ice and after incubated for 1 h with anti-FLAG M2 in blocking
buffer on ice. After 2 rinses with ice cold PBS, cells were fixed at RT with 4% PFA
for 15min, washed three times with PBS and incubated with conjugated secondary
for 1 h at RT. Cells were then treated as described above. For staining of fixed cells,
cells were treated as above with the only difference that cells were fixed at RT with
4% PFA for 15min before the blocking and the primary incubation and not after.
In this case all the incubations were performed at RT.
For phalloidin staining of zebrafish embryos, 24 hpf embryos were
dechorionated with pronase and fixed with 4% sweet PFA (4% paraformaldehyde
(PFA) in phosphate-saline buffer with 4% sucrose in PBS) for 3 h at RT. After two
5min washes in PBS Tween 0.1% (PBSTween), embryos were permeabilized with
PBSþTriton 2% and then stained ON with Alexa 488-conjugated phalloidin
(ThermoFisher, A12379) diluted 1:100 in PBSTween. After four 10min washes,
embryos were incubated with DAPI in PBSTween for nuclear staining and
additionally washed for 10min. Embryos were manually deyolked and laterally
mounted on slides with Fluoromount G (SouthernBiotech) for subsequent imaging.
Embryos that were not oriented appropriately were excluded from analysis. Images
were acquired using a confocal microscope LS710 with ZEN software (Carl Zeiss
AG) and analysed using ImageJ software.
For myosin staining of zebrafish, dechorionated embryos were fixed in 4% sweet
PFA and, after washing, were incubated in ice-cold methanol ON. After treatment
with proteinase K for permeabilization, embryos were incubated one hour at RT
with blocking solution (10% goat serum in PBSþ 1.5% Triton X-100 (PBST)) and
then ON with primary antibody against fast Myosin light chain (F310, DHBS
1:100) followed by six 30min washes in PBST and ON incubation with 594 Alexa-
conjugated goat anti-mouse antibody (1:500; ThermoFisher, A11032). After five
30min washes in PBST, samples were treated, mounted, and images captured as
described above.
For zebrafish histopathology, adult fish (five WT and three sex and age-matched
mutants) were killed in ice-cold water, fixed in 4% PFAþ 4% sucrose for 48 h,
decalcified in 50mM EDTA for 4 days, and then washed in PBS and serially
dehydrated in ethanol. Paraffin embedding, sectioning (5 mm thick) and H&E
staining of adult zebrafish were performed at Harvard Medical School Rodent
Histopathology Core. Images were collected using a dual view Nikon Eclipse 90i at
2, 10 and 40 magnification, and analysed using ImageJ.
RNA extraction and RT-PCR of MYMK. Total RNA from 30 embryos was col-
lected for MO4 injected and uninjected embryos using TRIzol (Invitrogen)
according to manufacturer’s specifications. RNA was then cleaned using RNeasy
Mini kit (QIAGEN) and total RNA quantified by Nanodrop (ThermoFisher).
1.2 mg of total extracted RNA was retrotranscribed using SuperScript First-Strand
Synthesis System (Invitrogen) with random hexamers to amplify any aberrant
transcript that does not contain a poly(A) tail. The resultant cDNA was used for
qualitative RT–PCR using the following three primers: z_mymk_E3, coding exon 3:
50-CCGGAGTAGAATGCCGTATCC-30 ; z_mymk_I2, intron 2: 50-
ACCTGTCAACATGCTCGTGAA-30 for aberrant transcript; z_mymk_E5, coding
exon 5: 50-TTGACTAGCAGGGCATCGTG-30 .
Total RNA was extracted from mouse tissue or cultured cells with TRIZOL
(Invitrogen) according to manufacturer instructions and contaminant DNA was
removed. cDNA was synthesized using Superscript III reverse transcriptase with
random hexamer primers (Invitrogen). Gene expression was analysed by qPCR
using KAPA SYBR FAST (Kapa Biosystems). The following primers were used for
Mymk analysis: F:50-CCTGCTGTCTCTCCCAAG-30 , R:50-AGAACCAGTGGGTC
CCTAA-30 ; 18S expression was used as a housekeeping gene. All analyses were
performed on a 7900HT Fast Real-Time PCR machine (Life Technologies).
Morpholino and mRNA injections. Plasmids containing human WT and mutant
MYMK coding sequence (described above) were linearized using NotI restriction
enzyme and the linear product purified using phenol/chloroform. These sequences,
containing the T7 promoter, were in-vitro transcribed using mMESSAGE mMA-
CHINE T7 ULTRA (Ambion) according to manufacturer’s conditions. This
allowed for the incorporation of ARCA cap and poly(A) tail into the growing
mRNA, generating a more stable RNA for injection in the embryo.
Four different morpholino sequences were designed and purchased from
GeneTools. Morpholino oligonucleotide sequences MO1: 50-ACTCACACAAA
TGCCCTGGCGATTT-30; MO2: 50-ACTCAGAGAAATGGCCTCGGGATTT-30;
MO3: 50-TCTTGGCGATAAACGCTCCCATTGC-30 ; MO4: 50-TTATTATTTG
CTCACCCAGTAGCGT-30 . Three were translation-blocking morpholinos
(MO1-3) of which two were previously published13 and the fourth was a
transcription-blocking morpholino targeting the donor site of exon 2
(Supplementary Fig. 6b). Stock solutions were diluted to 2 mgml 1 and optimal
injection conditions were ascertained by a dose-response curve. An optimal final
volume of 3 nl was injected into the embryo yolk at the one or two nuclei stage for
each morpholino. Morpholino against p53 at a ratio of 3:2 was coinjected with each
morpholino to reduce non-specific effects53. A control morpholino targeting the
human beta-globin gene was used to test injection conditions. A minimum of 100
embryos were injected during each session; only a small increase (less than 10%) of
embryo deaths was observed in morpholino injected versus uninjected embryos
after 24 h. For rescue experiments, an optimal dose of 100 pg of mRNA generated
from WT and mutant constructs (described above) were each independently co-
injected with MO4 in or proximal to the nuclei of at least 100 embryos at the 1 cell
stage. No evident toxicity was associated with mRNA injection.
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Rescue of mymkinsT/insTembryos. For rescue ofmymkinsT/insT zebrafish, 200 ng of
WT or mutant mRNA was injected into the yolk of one-cell stage embryos
obtained from F2 mymkinsT/WT crosses. To visualize the plasma membrane, 40 ng
of membrane-bound mCherry was injected in the yolk of 8- to 16-cell stage of the
same embryos to chimerically staining cell membranes. At least 100 embryos were
injected with each allele for 3 or more replicate experiments, each on a separate
day. We observed an average survival of 60% of the embryos after injection
independent of the injected mRNA. Embryos were collectively fixed in PFA 4% in
PBS and stained with DAPI. Each embryo was individually separated, the head was
dissected for DNA extraction (using 50mM NaOH stabilized with 10mM Tris HCl
pH 8) and genotyping, and the tail distal to the yolk sac was isolated in a single well
of 96 well plate. After genotyping, tails of mymkinsT/insT embryos were mounted
laterally in 80% glycerol and images acquired using a confocal microscope LS710
with ZEN software (Carl Zeiss AG). Analysis was blinded to the injected mRNA
and scored according to the nuclear organization. Number of mutant embryos per
genotype per injection were: mymkinsT/insTþmCherry¼ 3/4/4; mymkinsT/insTþ
WT¼ 7/7/8; mymkinsT/insTþM1¼ 8/3/8/2; mymkinsT/insTþM5¼ 2/5/5/2;
mymkinsT/insTþM3¼ 8/5/3/9; mymkinsT/insTþM2¼ 2/3/7/10.
Internuclear distance analysis. To quantify the distance between nuclei, ran-
domly selected images of 6 fish per allele (2 embryos from 3 different injections
each on a different day) were opened in ImageJ and the xy position of each nucleus
was annotated. The quantitative analysis of internuclear distances was performed
using a custom written program on MATLAB. The program takes the coordinates
of myonuclei as input, and gives the frequency distributions of the nucleus-nucleus
distance d, for each phenotype. It then compares these distributions with each
other and with the distribution produced by a random generated data set of xy
positions. The 2D random distribution was obtained starting from 6 computer
generated images, each with a number of objects equal to the average number and
size of nuclei found in the zebrafish images (mean 110 nuclei, St.Dev. 20). To not
overlap, any object with a distance o5 mm from any other was excluded, as zeb-
rafish myonuclei are B5 mm. The histograms were normalized to 80 mm, as this is
the peak, after which there is a decay due, in part, to the finite boundaries of the
200mm image. Histograms of the same genotype were then averaged together and
presented with SE bands. Deviations from the 2D random model were measured at
distance a (5–10 mm from the nucleus center that describes the nearest neighbor
organization) and distance b (18–28 mm from the nucleus center that describes the
row organization), and statistical significance was tested between all distributions
(6 distributions per genotype) using Two-Sample Kolmogorov-Smirnov test in
MATLAB (kstest2). The code used for the analysis is available on request. Data
were obtained from a minimum of two mutant embryos per clutch and three
clutches from separate injections on different days.
Statistical analyses and quantitation. Muscle biopsies. Significance of fiber size
(cross-sectional area and minimum Feret diameter) and number and nuclei
number were assessed with Student’s t-tests and ANOVA in Microsoft Excel.
Graphs for the muscle biopsy analysis were generated in Microsoft Excel with
mean±standard deviation reported. Po0.05 was considered significant.
Fusion assay. Analysis of fusion assay in transfected cells was performed on at
least six fields per experiment for three replicates. For transfection efficiency the
number of GFP-positive cells was counted for at least seven random fields per
condition and in three independent experiments. The number of membrane
positive FLAG cells was calculated in a similar fashion. For all cases significance
was calculated using GraphPad imposing ordinary one-way ANOVA statistical
analysis, using Bonferroni correction for multiple testing.
Human myoblasts. Analyses of differentiated myoblasts were performed on at
least 10 random fields per experiment, and 3 independent experiments were
performed. The fusion index was calculated as number of nuclei contained in
myosin-positive cells. The differentiation index was calculated as the percentage of
nuclei in myosin positive cells versus all nuclei in the field. Cell surface was
calculated for 45 different cells for each condition and reported in micrometer. In
both cases significance was calculated using two-tailed Student’s unpaired
t-test. For each data, mean±s.e.m. is reported. Po0.05 was considered
significant.
Zebrafish. To determine the number of nuclei within each zebrafish embryo
myotome, an area of B2,500mm2 close to sarcomere X was selected and outlined
in ImageJ, and the number of cells (visualized by phalloidin staining) and nuclei
inside each cell (visualized by DAPI staining) were counted. At least six
independent embryos for each condition were randomly selected for non-blinded
analysis from among those successfully mounted in the appropriate lateral
orientation. All statistical analyses were performed using GraphPad Prism and
differences between data were tested using two-tailed Student’s unpaired t-test.
Po0.05 was considered significant. For each data, mean±s.e.m. is reported.
For the qualitative analysis of nuclear organization in tmem8cinsT/insT rescued
embryos, DAPI stained optical sections of injected embryos were blindly
qualitatively separated in four categories based approximately to this scheme: no
rescue¼more than 90–100% of the nuclei in the figure were organized as the
mCherry injected mymkinsT/insT ; minimal rescue¼ 50–80% of the nuclei organized
as in the mCherry injected mymkinsT/insT (some rescue, but overall more similar to
mutant); partial rescue¼ 50–80% of the nuclei organized as in the mCherry
injected WT (not complete rescue but overall more similar to WT); rescued¼
80–100% of nuclei organized as in the mCherry WT. Images were obtained by a
minimum of two mutant embryos in at least three different days of injection.
Data availability. Data supporting the findings of this study are available from the
authors on request. Genomic and phenotype data from a subset of participants are
available through dbGAP with the Accession ID phs001383.v1.p1. Zebrafish line
mymkinsT/insT (CL201) is registered at ZFIN with record number ZDB-ALT-
170608-19.
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